Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability

• Published in: BMC psychiatry Vol. 16; no. 1; p. 398
• Main Authors: Malaguarnera, Giulia, Bertino, Gaetano, Chisari, Giuseppe, Motta, Massimo, Vecchio, Michele, Vacante, Marco, Caraci, Filippo, Greco, Carmela, Drago, Filippo, Nunnari, Giuseppe, Malaguarnera, Michele
• Format: Journal Article
• Language: English
• Published: England BioMed Central 15.11.2016
• Subjects: Adult; Antioxidants - administration & dosage; Antiviral Agents - administration & dosage; Anxiety; Anxiety - complications; Anxiety - diagnosis; Anxiety - physiopathology; Depression - complications; Depression - diagnosis; Depression - physiopathology; Double-Blind Method; Drug Therapy, Combination; Female; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - psychology; Humans; Interferon-alpha - administration & dosage; Male; Middle Aged; Psychiatric Status Rating Scales; Psychiatry; Ribavirin - administration & dosage; Silymarin - administration & dosage; Treatment Outcome; Work Performance; Silybin; Depression; Anxiety; Interferon; Hepatitis C; Work ability index
• ISSN: 1471-244X; 1471-244X
• DOI: 10.1186/s12888-016-1115-z

Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associa...